Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02997176 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
A Phase 1 study of Advanced Solid Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 11
- Study locations
NCT02997176: Completed Phase 1 study of Advanced Solid Tumors, sponsored by Pfizer.
NCT02997176 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Pfizer. The registered enrollment target is 38 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (81% lower). The trial reports 11 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02997176, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
Primary Outcome
AUC0-24 of talazoparib was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.
Conditions Studied
Interventions
- DRUG Talazoparib
Study Locations (11)
California
- UCLA Hematology/Oncology - Alhambra - Alhambra
- CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center - Bakersfield
- St. Joseph Heritage Healthcare - Fullerton
- St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare - Fullerton
- UCLA Hematology/Oncology - Los Angeles
- UCLA Hematology/Oncology - Porter Ranch - Porter Ranch
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
- UCLA Torrance Oncology - Torrance
- UCLA Hematology/Oncology - Santa Clarita - Valencia
Florida
- Orlando Health, Inc. - Orlando
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-09-30 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 1 |
What the finished NCT02997176 record still lists
NCT02997176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Talazoparib is the first listed.
NCT02997176 lists 11 locations in 3 states (California, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT02997176 about?
NCT02997176 is a clinical study titled "An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)". This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.
What is the current status of trial NCT02997176?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2016-09-30. Estimated completion is 2020-02-12.
What conditions does trial NCT02997176 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT02997176?
The interventions under investigation include: Talazoparib (DRUG).
Who is sponsoring clinical trial NCT02997176?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02997176 being conducted?
This trial has 11 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02997176's enrollment target sits among peer trials
38 112th of 144 higher than 33 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI